Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Lung Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms, Male 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 5Trastuzumab 4Taxes 4Docetaxel 4Paclitaxel 3Albumin-Bound Paclitaxel 3tipifarnib 2sargramostim 2liposomal doxorubicin 2Vorinostat 2Immunohistochemistry 2Granulocyte-Macrophage Colony-Stimulating Factor 2Filgrastim 2Enzyme-Linked Immunosorbent Assay 2Doxorubicin 2Capecitabine 2temsirolimus 1seviteronel 1romidepsin 1poly(I).poly(c12,U) 1pertuzumab 1pegfilgrastim 1oblimersen 1ixabepilone 1interferon gamma-1b 1flt3 ligand protein 1denileukin diftitox 1cixutumumab 1alvocidib 1Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms, Male × oblimersen × Clear all
NCT00063934 2019-03-05

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
31 enrolled 8 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡